Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct 26;29(46):8175-8.
doi: 10.1016/j.vaccine.2011.09.005. Epub 2011 Sep 13.

New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci

James B Dale  1 , Thomas A Penfound, Edna Y Chiang, William J Walton
Affiliations

New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci

James B Dale et al. Vaccine. .

Abstract

Our previous studies have shown that recombinant multivalent vaccines containing amino-terminal M protein fragments from as many as 26 different serotypes of group A streptococci (GAS) evoked opsonic antibodies in animals and humans. In the present study, we constructed a new 30-valent vaccine containing M protein peptides from GAS serotypes prevalent in North America and Europe. The vaccine was immunogenic in rabbits and evoked bactericidal antibodies against all 30 vaccine serotypes of GAS. In addition, the vaccine antisera also contained significant levels of bactericidal antibodies against 24 of 40 non-vaccine serotypes of GAS. These results indicate that the potential efficacy of the new multivalent vaccine may be greater than predicted based on the "type-specific" M peptides represented.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic diagram of the four proteins comprising the 30-valent M protein-based GAS vaccine. M subtypes were the parent sequence type (“.0”) unless otherwise indicated.
Fig. 2
Fig. 2
(2.A.) Geometric mean antibody levels (Log2) evoked in three rabbits after immunization with three 800 µg doses of the 30-valent GAS vaccine. Solid-phase antigens were recombinant dimeric peptides or synthetic peptides (indicated by an asterisk) copying the sub-peptides. (2.B.) Bactericidal antibodies evoked by 30-valent M protein-based GAS vaccine. Immune serum from one of the rabbits immunized with 800 µg doses of the vaccine was used in bactericidal assays against all vaccine serotypes of GAS. Percent killing was calculated as described in Materials and Methods.
Fig. 3
Fig. 3
Bactericidal antibodies evoked by 30-valent vaccine against non-vaccine serotypes of GAS.
See this image and copyright information in PMC

References

    1. Steer AC, Batzloff MR, Mulholland K, Carapetis JR. Group A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis. 2009;22(6):544–552. - PubMed
    1. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA. 2004;292(6):709–715. - PubMed
    1. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis. 2005;41(8):1114–1122. - PubMed
    1. Dale JB. Current status of group A streptococcal vaccine development. Adv Exp Med Biol. 2008;609:53–63. - PubMed
    1. Dale JB. Multivalent group A streptococcal vaccines. Inf Dis Clin N Amer. 1999;13:227–243. - PubMed

Publication types

MeSH terms